Figure 12
From: Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein
Mass spectrometric analysis of the Δ71-82 αS used for neonatal brain injection. To verify that Δ71-82 αS was the correct protein and its integrity, we performed mass spectrometry and compared the molecular mass to full length αS. Up panel, recombinant full-length human αS wild type; bottom panel, recombinant human Δ71-82 αS.